百利天恆(688506.SH)：iza-bren(EGFR×HER3雙抗ADC)用於治療複發性或轉移性食管鱗癌被納入優先審評程序

Core Viewpoint - The company, Bai Li Tian Heng, has announced that its self-developed drug, iza-bren, a first-in-class EGFR×HER3 dual antibody ADC, has been included in the priority review list by the National Medical Products Administration's Center for Drug Evaluation (CDE) [1] Group 1 - Iza-bren is the world's first EGFR×HER3 dual antibody ADC to enter the Phase III clinical stage [1] - The inclusion in the priority review list signifies a significant milestone for the company and its innovative drug development [1]